JP2010522137A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010522137A5 JP2010522137A5 JP2009540891A JP2009540891A JP2010522137A5 JP 2010522137 A5 JP2010522137 A5 JP 2010522137A5 JP 2009540891 A JP2009540891 A JP 2009540891A JP 2009540891 A JP2009540891 A JP 2009540891A JP 2010522137 A5 JP2010522137 A5 JP 2010522137A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- effective amount
- risperidone
- day
- hydroxyrisperidone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 28
- RAPZEAPATHNIPO-UHFFFAOYSA-N Risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 claims 8
- 229960001534 Risperidone Drugs 0.000 claims 8
- 230000001058 adult Effects 0.000 claims 8
- PMXMIIMHBWHSKN-UHFFFAOYSA-N 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCC(O)C4=NC=3C)=NOC2=C1 PMXMIIMHBWHSKN-UHFFFAOYSA-N 0.000 claims 7
- 238000009472 formulation Methods 0.000 claims 4
- 206010060800 Hot flush Diseases 0.000 claims 2
- 206010029410 Night sweats Diseases 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 230000036565 night sweats Effects 0.000 claims 2
- 208000002173 Dizziness Diseases 0.000 claims 1
- 206010019233 Headache Diseases 0.000 claims 1
- 208000008454 Hyperhidrosis Diseases 0.000 claims 1
- 206010028813 Nausea Diseases 0.000 claims 1
- 206010033557 Palpitations Diseases 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 230000003054 hormonal Effects 0.000 claims 1
- 230000009245 menopause Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000035900 sweating Effects 0.000 claims 1
Claims (17)
- 閉経周辺期又は閉経期に関連するホルモン変化の1以上の症状を治療する又は予防するための医薬組成物であって、有効量のリスペリドン及び/又は9−ヒドロキシリスペリドンを含み、ここで、該症状は、のぼせ、動悸、おびただしい発汗、寝汗、めまい、頭痛、及び悪心からなる群から選ばれる、前記組成物。
- 前記症状が、のぼせ、及び/又は寝汗である、請求項1に記載の組成物。
- リスペリドンが投与される、請求項1に記載の組成物。
- リスペリドンの有効量が、成人患者に関して0.1〜50mg/日である、請求項3に記載の組成物。
- リスペリドンの有効量が、成人患者に関して0.1〜20mg/日である、請求項3に記載の組成物。
- リスペリドンの有効量が、成人患者に関して0.1〜6mg/日である、請求項3に記載の組成物。
- リスペリドンの有効量が、成人患者に関して0.1〜2mg/日である、請求項3に記載の組成物。
- 9−ヒロロキシリスペリドンが投与される、請求項1に記載の組成物。
- リスペリドンの有効量が、医薬として許容される製剤を用いて投与される、請求項3に記載の組成物。
- 前記医薬として許容される製剤は、経口製剤、注射製剤、吸入製剤、及び経皮パッチからなる群から選ばれる、請求項9に記載の組成物。
- 9−ヒドロキシリスペリドンの有効量が、成人患者に関して0.1〜50mg/日である、請求項8に記載の組成物。
- 9−ヒドロキシリスペリドンの有効量が、成人患者に関して0.1〜20mg/日である、請求項8に記載の組成物。
- 9−ヒドロキシリスペリドンの有効量が、成人患者に関して0.1〜6mg/日である、請求項8に記載の組成物。
- 9−ヒドロキシリスペリドンの有効量が、成人患者に関して0.1〜2mg/日である、請求項8に記載の組成物。
- 9−ヒドロキシリスペリドンの有効量が、医薬として許容される製剤を用いて投与される、請求項8に記載の組成物。
- 前記医薬として許容される製剤は、経口製剤、注射製剤、吸入製剤、及び経皮パッチからなる群から選ばれる、請求項15に記載の組成物。
- リスペリドンと9−ヒロロキシリスペリドンの混合物が投与される、請求項1に記載の組成物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/638,282 US7645750B2 (en) | 2006-12-13 | 2006-12-13 | Method of treating symptoms of hormonal variations |
PCT/IB2007/004514 WO2008087491A2 (en) | 2006-12-13 | 2007-11-27 | Method for treating or preventing symptoms of hormonal variations |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2010522137A JP2010522137A (ja) | 2010-07-01 |
JP2010522137A5 true JP2010522137A5 (ja) | 2010-08-26 |
JP4643742B2 JP4643742B2 (ja) | 2011-03-02 |
Family
ID=39528142
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009540891A Expired - Fee Related JP4643742B2 (ja) | 2006-12-13 | 2007-11-27 | ホルモン変化の症状を治療する又は予防するための方法 |
Country Status (11)
Country | Link |
---|---|
US (3) | US7645750B2 (ja) |
EP (1) | EP2101781B1 (ja) |
JP (1) | JP4643742B2 (ja) |
KR (1) | KR101435695B1 (ja) |
CN (2) | CN102697785B (ja) |
AT (1) | ATE506065T1 (ja) |
CA (1) | CA2671954C (ja) |
DE (1) | DE602007014102D1 (ja) |
MY (1) | MY162095A (ja) |
TW (1) | TWI330083B (ja) |
WO (1) | WO2008087491A2 (ja) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ527142A (en) | 2003-07-23 | 2006-03-31 | Douglas Pharmaceuticals Ltd | A stable suspension formulation |
US8631151B2 (en) | 2006-05-18 | 2014-01-14 | Intel Corporation | Techniques for guaranteeing bandwidth with aggregate traffic |
US7645750B2 (en) * | 2006-12-13 | 2010-01-12 | Yung Shin Pharmaceutical Ind. Co., Ltd. | Method of treating symptoms of hormonal variations |
CA2673481A1 (en) * | 2006-12-19 | 2008-06-26 | University Of Virginia Patent Foundation | Combined effects of topiramate and ondansetron on alcohol consumption |
CA2697990A1 (en) * | 2007-08-27 | 2009-03-05 | University Of Virginia Patent Foundation | Medication combinations for the treatment of alcoholism and drug addiction |
US8420624B2 (en) * | 2007-12-04 | 2013-04-16 | Yung Shin Pharm. Ind. Co., Ltd. | Methods for treating or preventing symptoms of hormonal variations |
NZ588037A (en) | 2008-02-28 | 2012-08-31 | Univ Virginia Patent Found | Serotonin transporter gene SLC6A4 and treatment of alcoholism |
US8461102B2 (en) | 2010-03-02 | 2013-06-11 | George E. Royster, JR. | Methods and compositions for treating and preventing symptoms of hormonal variations |
AU2011223807B2 (en) * | 2010-03-02 | 2016-05-12 | Fervent Pharmaceuticals, Llc | Methods and compositions for treating or preventing symptoms of hormonal variations |
US20130190299A1 (en) * | 2010-06-30 | 2013-07-25 | Victoria Link Ltd. | Methods and compositions for treatment of multiple sclerosis |
UA116615C2 (uk) * | 2010-07-02 | 2018-04-25 | Юніверсіті Оф Вірджінія Петент Фаундейшн | Застосування ондансетрону у лікуванні хвороби чи розладу, пов'язаних з алкоголем |
WO2012154174A1 (en) * | 2011-05-10 | 2012-11-15 | Liu Chui Yu | Methods for treating insomnia |
CA2848211A1 (en) | 2011-09-09 | 2013-03-14 | University Of Virginia Patent Foundation | Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence |
CN105744835A (zh) | 2013-07-22 | 2016-07-06 | 俄亥俄州国家创新基金会 | 用于减少热潮红发生的方法 |
US11147856B2 (en) * | 2015-04-07 | 2021-10-19 | Meiji Co., Ltd. | Hot flash-suppressing agent |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4096254A (en) * | 1976-05-10 | 1978-06-20 | Richardson-Merrell Inc. | Method of treating the symptoms of menopause and osteoporosis |
FR2358892A1 (fr) * | 1976-07-19 | 1978-02-17 | Ile De France | N(1'-allyl 2'-pyrrolidylmethyl)2,3-dimethoxy 5-sulfamoyl benzamide, ses derives |
US5654011A (en) * | 1996-07-30 | 1997-08-05 | Energetics, Inc. | Dietary supplements |
EP1028690A2 (en) * | 1997-10-20 | 2000-08-23 | Novo Nordisk A/S | Luteinising hormone antagonists useful for treatment of estrogen deficiencies, or as a contraceptive |
FR2779579B1 (fr) * | 1998-06-09 | 2000-08-25 | Thomson Csf | Dispositif de commande optique pour l'emission et la reception d'un radar large bande |
EP1202725B1 (en) * | 1999-07-22 | 2007-04-11 | University Of Rochester | Method of treating symptoms of hormonal variation, including hot flashes |
US6613792B1 (en) * | 1999-08-02 | 2003-09-02 | Designed Nutritional Products, Inc. | Treatment of premenstrual syndrome and menopause |
ES2212737B1 (es) * | 1999-08-13 | 2005-10-01 | Vela Pharmaceuticals Inc. | Ciclobenzaprina para tratar trastornos de ansiedad generalizada y composiciones de la misma. |
US20040002482A1 (en) * | 2000-08-30 | 2004-01-01 | Dudley Robert E. | Androgen pharmaceutical composition and method for treating depression |
PL364580A1 (en) * | 2001-03-29 | 2004-12-13 | Bristol-Myers Squibb Company | Cyclopropylindole derivatives as selective serotonin reuptake inhibitors |
WO2003037334A1 (en) * | 2001-10-31 | 2003-05-08 | Merck & Co., Inc. | Method for treating or preventing symptoms of hormonal variation including hot flashes |
CN1465348A (zh) | 2002-07-05 | 2004-01-07 | 冯威健 | 复方消融合剂及其在用作制备治疗肿瘤药物上的应用 |
US20040127489A1 (en) * | 2002-07-29 | 2004-07-01 | David Pickar | Novel antipsychotic combination therapies and compositions useful therein |
US20040063721A1 (en) * | 2002-08-15 | 2004-04-01 | Wyeth | Agonism of the 5HT2A receptor for treatment of thermoregulatory dysfunction |
JP2006514633A (ja) * | 2002-11-26 | 2006-05-11 | アレックザ ファーマシューティカルズ, インコーポレイテッド | 吸入によって送達される抗精神病薬を用いた頭痛の治療 |
US7855195B2 (en) * | 2003-12-02 | 2010-12-21 | Pharmaneuroboost N.V. | Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
MXPA06013163A (es) * | 2004-05-11 | 2007-02-13 | Pfizer Prod Inc | Combinacion de antipsicoticos atipicos y antagonistas del receptor 5-ht1b. |
WO2005120523A1 (en) * | 2004-06-04 | 2005-12-22 | Mood Management Sciences, Llc | Methods and compositions for treating mood disorder |
TW200631584A (en) | 2004-11-15 | 2006-09-16 | Akzo Nobel Nv | A medicament related to mirtazapine for the treatment of hot flush |
WO2006055854A2 (en) * | 2004-11-17 | 2006-05-26 | Cypress Bioscience, Inc. | Methods for reducing the side effects associated with mirtazapine treatment |
US7645750B2 (en) * | 2006-12-13 | 2010-01-12 | Yung Shin Pharmaceutical Ind. Co., Ltd. | Method of treating symptoms of hormonal variations |
-
2006
- 2006-12-13 US US11/638,282 patent/US7645750B2/en active Active
-
2007
- 2007-10-26 TW TW096140356A patent/TWI330083B/zh not_active IP Right Cessation
- 2007-11-27 KR KR1020097012120A patent/KR101435695B1/ko active IP Right Grant
- 2007-11-27 CN CN201210178935.XA patent/CN102697785B/zh not_active Expired - Fee Related
- 2007-11-27 WO PCT/IB2007/004514 patent/WO2008087491A2/en active Application Filing
- 2007-11-27 AT AT07872103T patent/ATE506065T1/de not_active IP Right Cessation
- 2007-11-27 JP JP2009540891A patent/JP4643742B2/ja not_active Expired - Fee Related
- 2007-11-27 EP EP07872103A patent/EP2101781B1/en not_active Not-in-force
- 2007-11-27 CA CA2671954A patent/CA2671954C/en active Active
- 2007-11-27 MY MYPI20092347A patent/MY162095A/en unknown
- 2007-11-27 DE DE602007014102T patent/DE602007014102D1/de active Active
- 2007-11-27 CN CN2007800463514A patent/CN101588804B/zh not_active Expired - Fee Related
-
2009
- 2009-12-11 US US12/636,552 patent/US20100093762A1/en not_active Abandoned
-
2015
- 2015-03-03 US US14/637,200 patent/US20150246056A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2010522137A5 (ja) | ||
JP5781062B2 (ja) | 不快な味を有する薬物を含有するフィルム製剤 | |
JP2009525343A5 (ja) | ||
HRP20121072T1 (hr) | Postupci za davanje tetrahidrobiopterina, povezani pripravci i postupci mjerenja | |
CN102892418A (zh) | 含烟碱的药物组合物 | |
AR075735A1 (es) | Composiciones farmaceuticas de liberacion inmediata que comprenden oxicodona y naloxona. uso | |
JP2010525050A5 (ja) | ||
HRP20150644T1 (hr) | Metoda za lijeäśenje atrijalne fibrilacije | |
JP2010222367A5 (ja) | ||
AR062167A1 (es) | Sistema de administracion gastrorretentivo | |
JP2009517411A5 (ja) | ||
JP2009518293A5 (ja) | ||
CA2671954A1 (en) | Methods for treating or preventing symptoms of hormonal variations | |
JP2017535613A5 (ja) | ||
NZ613291A (en) | Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof | |
Lee et al. | Tramadol 37.5-mg/acetaminophen 325-mg combination tablets added to regular therapy for rheumatoid arthritis pain: a 1-week, randomized, double-blind, placebo-controlled trial | |
NZ587202A (en) | Methods for measuring a patient response upon administration of a drug and compositions thereof | |
JP2013516493A5 (ja) | ||
WO2013123623A1 (zh) | 一种口腔崩解片及其制备方法 | |
Wang et al. | Intracerebral administration of ultrasound-induced dissolution of lipid-coated GDNF microbubbles provides neuroprotection in a rat model of Parkinson's disease | |
JP2016505050A5 (ja) | ||
TW200946142A (en) | Tablet | |
JP2011500589A5 (ja) | ||
JP2009534367A5 (ja) | ||
WO2008120966A1 (es) | Composición farmacéutica en forma de tableta sublingual que comprende un antiinflamatorio no esteroideo y un analgésico opiáceo para el manejo del dolor. |